Loading stock data…
Kenvue Inc (KVUE)
$19.07-0.06 (-0.31%)
Market ClosedLast close Jun 29
Kenvue Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kenvue Inc. in the Consumer Defensive sector is trading at $19.07 with a market capitalization of $35.5B. Wall Street consensus targets $19.50 (12 analysts), implying a +2.3% move over the next 12 months. The stock is currently 17% below its 52-week high of $22.87, remaining 12.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.91B↑ | $3.78B↑ | $3.76B↓ | $3.84B↑ | $3.74B |
| Gross Profit | $2.30B↑ | $2.14B↓ | $2.23B↓ | $2.26B↑ | $2.17B |
| Operating Income | $838.00M↑ | $632.00M↓ | $713.00M↓ | $752.00M↑ | $618.00M |
| Net Income | $474.00M↑ | $330.00M↓ | $398.00M↓ | $420.00M↑ | $322.00M |
Peer Comparison
Fundamentals
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Healt...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.48B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
3.30%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.29%
Volume
Today's trading volume
21.08M
Recent News
Are Consumer Staples Stocks Lagging Hormel Foods (HRL) This Year?
Here is how Hormel Foods (HRL) and Kenvue (KVUE) have performed compared to their sector so far this year.
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
5 High-Yielding Dividend Kings Retirees and Boomers Can Buy Today and Safely Hold Forever
While many Baby Boomers have enjoyed a long bull market over the past 35 years, there comes a point when income becomes more critical than stock appreciation. The reason is simple: those who leave their careers to enjoy a well-deserved retirement lose the benefits of a regular salary and their jobs, such as 401(k) matching ... 5 High-Yielding Dividend Kings Retirees and Boomers Can Buy Today and Safely Hold Forever
Piper Sandler Raises Kimberly-Clark (KMB) Price Target, Sees Long-Term Upside from Kenvue Deal
Kimberly-Clark Corporation (NASDAQ:KMB) is included among the Dividend Stock Portfolio: Top 10 Stocks to Buy According to Reddit. On June 17, Piper Sandler raised its price recommendation on Kimberly-Clark Corporation (NASDAQ:KMB) to $121 from $115. It reiterated an Overweight rating on the stock. The firm said that potential benefits from Kimberly-Clark’s deal with Kenvue (KVUE) […]
J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030
Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.